Latest news with #Statera
Times
27-05-2025
- Business
- Times
Two big UK battery storage developers favour zonal pricing
Two of Britain's biggest battery storage developers have come out in favour of regional electricity pricing, despite opposition from their peers who argue that the radical shake-up will deter investment. Gresham House and Statera both told The Times that zonal pricing would cut the costs of operating Britain's energy system, ensuring that batteries were built in the right locations to help deal with surplus wind power. Ben Guest, head of energy transition at Gresham House, operator of the UK's largest battery storage fleet, said it believed zonal pricing was 'an essential step for the UK's electricity system' to help 'motivate investment where it is most needed'. The government is expected to decide imminently whether to ditch Britain's national wholesale electricity price and introduce a system with about seven to twelve regional zones. Prices in each zone would vary depending on the supply and demand balance in the area, ensuring that wind farms in remote locations could not sell their electricity to consumers at the other end of the country if there were not sufficient cables to physically deliver the power. At present the National Electricity System Operator spends hundreds of millions of pounds every year dealing with such cabling constraints by paying wind farms to switch off and gas plants nearer demand to fire up and replace them. Batteries installed near wind farms could address the problem by storing surplus power when it is windy and discharging it in calm weather, smoothing out supplies. However the national market does not always provide the correct price signals: batteries in Scotland might discharge because the national price is high, even if their area is already swamped with power. In a zonal system, the excess power would depress the regional price, encouraging the battery to charge up. Zonal pricing is highly divisive in the energy industry, with wind farm developers and other generators generally opposed and some household suppliers and consumer groups in favour. Guest said Gresham's analysis showed that 'a well-designed zonal pricing system can reduce wholesale energy costs and reduce the need for a lot of the planned electricity network upgrades and associated pylons'. Zonal pricing would 'incentivise energy storage, the cost of which has been falling sharply, to store renewable energy when generation exceeds demand and then deliver it across zonal boundaries when renewable generation is low and constraint limits are not reached', he said. Tom Vernon, chief executive of Statera Energy, which is building Britain's largest battery storage site at Trafford Park in Greater Manchester, said: 'Developing and dispatching batteries in the right locations is critical for cost-effectively balancing the grid. At Statera, we support zonal pricing because it will make the power system more transparent, and provide a clear price signal for the efficient operation and location of demand and generation.' He said he was 'confident that zonal pricing will lower costs in the long run'. However, other leading battery storage developers said they opposed the change. Harmony Energy said it feared that 'the uncertainty created by such a fundamental shift in market design creates an unnecessary risk in relation to investor confidence at a time when the country needs to get on building out critical infrastructure'. And Amit Gudka, chief executive of Field, said zonal pricing would 'slow down investment' and building out the network should be the priority instead of 'tinkering with the market'. Zenobe, another battery storage company, has claimed that even the prospect of zonal pricing has already 'slashed investor confidence and is inhibiting battery build-out', as the complexity and uncertainty of zonal pricing makes it harder to secure agreements to sell power. A spokesman for the Department for Energy Security and Net Zero said: 'We are considering reforms to Britain's electricity market arrangements, ensuring that these focus on protecting bill-payers and encouraging investment. We will provide an update in due course.'
STV News
25-04-2025
- Business
- STV News
Green hydrogen project granted planning permission by council
A green hydrogen project said to be the largest in the UK has obtained planning approval from Aberdeenshire Council. Statera Energy says the Kintore hydrogen facility could deliver £400m to the Aberdeenshire economy and support the transition of industrial clusters like Grangemouth, as well as providing thousands of jobs. The facility will produce hydrogen through electrolysis, using surplus wind power which would otherwise be turned off to balance the grid. It is initially planned to have a storage capacity of 500MW before scaling up to 3GW. Statera says hydrogen produced at Kintore could be supplied to the UK's most carbon-intensive industrial clusters through existing gas transmission pipelines. The UK-based company says the project will result in around 3,000 jobs during construction and 300 permanent jobs once it is operational. Planning permission in principle was granted by a full meeting of Aberdeenshire Council on Thursday. A report which went before councillors noted the 'significant' impact it would have on the local landscape but said the benefits in offsetting carbon emissions outweighed these. Tom Vernon, chief executive of Statera Energy, said: 'We are delighted to have secured planning approval for Kintore. 'Over the coming years, the sheer volume of wind generation coming on to the system in the UK will make electrolysers critical for harnessing wind energy that would otherwise go to waste. 'Kintore Hydrogen is designed to fully capitalise on the potential that hydrogen has to offer. 'The location and scale of this project means it can make best use of surplus wind power, significantly lowering hydrogen production costs. 'It will help balance the grid, contribute to the UK's energy security, and support the decarbonisation of the UK's hard-to-abate industries and power sector.' Get all the latest news from around the country Follow STV News Scan the QR code on your mobile device for all the latest news from around the country
The Herald Scotland
25-04-2025
- Business
- The Herald Scotland
Kintore hydrogen facility in Aberdeenshire approved
The facility will produce hydrogen through electrolysis, using surplus wind power which would otherwise be turned off to balance the grid. It is initially planned to have a storage capacity of 500MW before scaling up to 3GW. Statera says hydrogen produced at Kintore could be supplied to the UK's most carbon-intensive industrial clusters through existing gas transmission pipelines. The UK-based company says the project will result in around 3,000 jobs during construction and 300 permanent jobs once it is operational. READ MORE: Planning permission in principle was granted by a full meeting of Aberdeenshire Council on Thursday. A report which went before councillors noted the 'significant' impact it would have on the local landscape but said the benefits in offsetting carbon emissions outweighed these. Tom Vernon, chief executive of Statera Energy, said: 'We are delighted to have secured planning approval for Kintore. 'Over the coming years, the sheer volume of wind generation coming on to the system in the UK will make electrolysers critical for harnessing wind energy that would otherwise go to waste. 'Kintore Hydrogen is designed to fully capitalise on the potential that hydrogen has to offer. 'The location and scale of this project means it can make best use of surplus wind power, significantly lowering hydrogen production costs. 'It will help balance the grid, contribute to the UK's energy security, and support the decarbonisation of the UK's hard-to-abate industries and power sector.'
Yahoo
12-02-2025
- Business
- Yahoo
Tivic Health Acquires Exclusive Worldwide Rights to Phase III TLR5 Agonist from Statera Biopharma
Broad licensing agreement accelerates Tivic's transformation into a diversified therapeutics company, adds late-stage immunotherapeutic to clinical pipeline. Potential for FDA approval within 24 months. FREMONT, Calif., February 12, 2025--(BUSINESS WIRE)--Tivic Health Systems, Inc., (Nasdaq: TIVC) today announced it has acquired worldwide exclusive license rights from Statera Biopharma (OTC: STAB) to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod™ for the treatment of acute radiation syndrome (ARS). In addition, the company has acquired an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta™. This broad licensing agreement establishes Tivic as a diversified therapeutics company, with complementary bioelectronic and biologic product candidates in its clinical pipeline. "Today, we have aggressively accelerated Tivic's strategic transformation from a single-product, direct-to-consumer company to a diversified therapeutics company—one with a growing pipeline of clinically validated product candidates," said Jennifer Ernst, Chief Executive Officer of Tivic. "Statera's TLR5 immunotherapy program strongly complements our work on non-invasive vagus nerve stimulation, positioning us to address immune and autonomic dysregulation—and associated diseases—through both neural and molecular pathways." The lead product candidate in the licensing program is a TLR5 agonist, Entolimod for the treatment of acute radiation syndrome (ARS). Market research firm CoherentMI estimates the global acute radiation syndrome (ARS) market to be valued at USD 5.2 billion in 2024 with a compound annual growth rate of five percent from 2024 to 2031. CoherentMI goes on to identify Statera Biopharma as one of the key market leaders. Entolimod and its immunologically optimized derivative, Entalasta, have been the subject of more than forty animal and human trials and $140 million of prior investment. The FDA has granted Fast Track and Orphan Drug designation to Entolimod for the prevention or treatment of ARS and to prevent death following a potential lethal dose of total body ionization irradiation during or after a radiation disaster. "Based on extensive prior research, development and numerous clinical trials of Entolimod, this important immunotherapy drug will now be advanced through the final steps toward a BLA filing and potential FDA approval under the skilled execution of the Tivic team," added Michael K. Handley, Chief Executive Officer of Statera. "We believe this agreement has the potential to provide considerable value for both Statera and Tivic shareholders." About the TLR5 Immunotherapy Program TLRs play a key role in the innate immune system. Entolimod's mechanism of action provides unique, highly sought-after attributes in the treatment of radiation-related illness. For ARS, animal studies have shown a three-fold increase in survival with a single dose 25-hours after exposure to lethal levels of radiation. Entolimod was effective without additional supportive care, showed gastrointestinal protective attributes, and exhibited no dose-limiting toxicity at even the highest dosing levels. Other studies have shown the potential to address additional applications. Tivic has secured exclusive options to these indications subject to certain milestones and payment conditions. These include: Immunosenescence - the gradual age-related decline in the immune system's ability to fight infections and respond to vaccines. Lymphocyte exhaustion – a condition in which immune cells, particularly T cells, become less effective after being exposed to infection, cancer, and/or cancer treatments. Neutropenia - a condition characterized by an abnormally low number of neutrophils, which can result from chemotherapy, radiation, bone marrow disorders, and certain autoimmune conditions. Vaccine enhancement – use as a vaccine adjuvant to enhance immune response to vaccines. Chronic radiation syndrome - a condition caused by long-term exposure to low levels of radiation that gradually damages tissues and organs. Terms of the Agreement Under the agreement, Tivic will initially pay Statera $1,200,000 in equity consideration and $300,000 cash to Statera for the use of Entolimod to treat ARS. Tivic can, at its discretion, subsequently add one or more indications, as well as expand its license to include an Entolimod derivative, Entalasta, by exercising the exclusive options granted in the agreement. Tivic has no obligation to exercise such options on any specific timeline or at all; but should it do so, Tivic agrees to fund development of each such indication. Additional future payments will be royalty and milestone-driven, ensuring alignment with the clinical and commercial success of Entolimod and, after exercise of the option granted in the agreement, Entalasta. Importantly, the structure of the agreement allows Tivic to strategically manage its investment while maximizing potential returns in line with shareholder interests. Select team members of Statera will join Tivic to establish Tivic's biopharmaceutical capabilities and advance product candidates towards commercialization. The transaction also includes exclusive rights and options for more than sixty patents and patents pending, associated know-how, and ownership of previously manufactured and tested materials. Additional information about this news, including an informational PowerPoint presentation, will be available at: Craft Capital Management LLC acted as the sole and exclusive investment banking firm in the transaction. About Tivic Health Tivic Health is a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health. Tivic Health takes a multi-pronged approach to treating diseases caused by immune dysregulation and dysautonomia. The complement of bioelectronic and biologic medicines allows Tivic to target disorders and disease via both neural pathways and molecular approaches. Tivic Health's first FDA approved product ClearUP™ is clinically proven to treat sinus pain and pressure. ClearUP is available through online retailers and commercial distributors. For more information about Tivic Health, visit: About Statera Biopharma Statera Biopharma, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. Statera has a large platform of toll-like receptor (TLR) agonists with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and Entalasta. Statera has clinical and preclinical programs for Crohn's disease (STAT-201), hematology (Entolimod) and inflammation (STAT-300) in addition to potential expansion into fibromyalgia and multiple sclerosis. To learn more about Statera, visit Forward-Looking Statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," and "intend," among others. These forward-looking statements are based on Tivic's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to Tivic's ability to maintain its Nasdaq listing; the development of Tivic's vaccine candidates; the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any vaccine under development, there are significant risks in the development, regulatory approval, and commercialization of new products. Tivic does not undertake an obligation to update or revise any forward-looking statement. Investors should read Tivic's filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024, under the heading "Risk Factors", as well as the company's subsequent filings with the SEC. All of Tivic's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof. View source version on Contacts Investor Contact Information: Hanover International,
